Beta-1,6-D-Glucan Oligomers for IgG2 Antibody Recognition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents based on β-1,6-D-glucans lack specificity in targeting immune cells, such as cancer cells, due to limited recognition by IgG2 antibodies and inefficient activation of immune responses.
Innovation Solution
Development of novel β-1,6-D-glucan compositions with specific oligomeric structures and moieties that can be conjugated to targeting moieties, allowing recognition by IgG2 antibodies and enhanced immune activation, including dendrimer molecules with β-1,6-D-glucan moieties linked through glycosidic linkages to a common core.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional β-1,6-D-glucan therapeutic agents are used, then immune activation is achieved, but specificity in targeting immune cells such as cancer cells is insufficient
Solution Approach 1:
The patent introduces specific oligomeric structures with defined n values (number of glucose units) and specific molecular weight ranges to create localized structural features that are recognized by IgG2 antibodies. This local structural optimization enables selective binding to immune cells while maintaining the overall glucan structure for immune activation.
Solution Approach 2:
The patent systematically varies critical parameters including the number of glucose units (n), molecular weight, and degree of branching to optimize both antibody recognition and immune cell targeting. By controlling these parameters within specific ranges, the invention achieves enhanced specificity while maintaining therapeutic efficacy.
2Reliability
If β-1,6-D-glucans are conjugated to targeting moieties, then targeting capability is improved, but complexity of the therapeutic agent increases
Solution Approach 1:
The patent divides the therapeutic agent into distinct functional segments: the β-1,6-D-glucan core structure for immune activation, the oligomeric unit with specific n values for antibody recognition, and the targeting moiety for cell-specific delivery. This segmentation allows each component to perform its function independently while simplifying the overall design and manufacturing process.
Solution Approach 2:
The patent employs the oligomeric β-1,6-D-glucan structure with specific molecular weight ranges as an intermediary that bridges the immune activation function and the targeting function. This intermediary structure is recognized by IgG2 antibodies and facilitates the connection between the glucan core and targeting moieties, reducing overall system complexity.
3Adaptability or versatility
If oligomeric structures with specific sizes are used, then recognition by IgG2 antibodies is enhanced, but manufacturing precision requirements increase
Solution Approach 1:
The patent uses naturally occurring β-1,6-D-glucan structures from fungal cell walls as templates, copying their essential oligomeric features and molecular weight characteristics. This approach simplifies manufacturing by leveraging biological synthesis pathways that naturally produce the required structural precision, avoiding the need for complex chemical synthesis control.
Solution Approach 2:
The patent designs a universal oligomeric structure with specific n values and molecular weight ranges that can be produced through standardized manufacturing processes. This universal structure serves multiple functions: immune activation, antibody recognition, and conjugation to various targeting moieties, reducing the need for multiple precision-controlled variants.
Data Source
AI summary
This invention relates to modifications of β-1,6-D-glucans, e.g., structures according to Formula (I), and the ability of these compositions to modulate an immune response.